secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-040894
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA Q2 net loss $27.9M, cash $510.1M; starts Phase 2/3 registrational trial for darovasertib
--------------------------------------------------------------------------------

- Net loss of $27.9M for Q2 2023; accumulated deficit $287.0M; cash and securities $510.1M, funding into 2027.
- Initiated Phase 2/3 registrational trial for darovasertib/crizotinib in first-line HLA-A2(-) metastatic uveal melanoma.
- First patient dosed in Amgen-sponsored Phase 1/2 trial of IDE397 (MAT2A) + AMG 193 in MTAP-deletion solid tumors.
- Anticipating FDA IND clearance in Q3 2023 for GSK101 Pol Theta Helicase inhibitor; $7M milestone due from GSK.
- Targeting Werner Helicase development candidate with GSK in H2 2023, with potential $3M milestone from GSK.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017023040894/0000950170-23-040894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017023040894/idya-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer